Streamlined Generation of CRISPR/Cas9-Mediated Single-Cell Knockout Clones in Murine Cell Lines.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
received:
22
11
2023
revised:
02
04
2024
accepted:
04
04
2024
pmc-release:
02
05
2025
medline:
16
5
2024
pubmed:
16
5
2024
entrez:
16
5
2024
Statut:
epublish
Résumé
Clonal cell lines harboring loss-of-function mutations in genes of interest are crucial for studying the cellular functions of the encoded proteins. Recent advances in genome engineering have converged on the CRISPR/Cas9 technology to quickly and reliably generate frameshift mutations in the target genes across various cell lines and species. Although high on-target cleavage efficiencies can be obtained reproducibly, screening and identifying clones with loss-of-function alleles remains a major bottleneck. Here, we describe a single sgRNA strategy to generate CRISPR/Cas9-mediated frameshift mutations in target genes of mammalian cell lines that can be easily and cost-effectively identified. Given the proliferation of workhorse cell lines such as N2a cells and the resulting clonal expansion of the cell type, our protocol can facilitate the isolation of knockout clonal cell lines and their genetic validation within a period of down to 6-8 weeks.
Identifiants
pubmed: 38751646
doi: 10.1021/acsptsci.3c00338
pmc: PMC11091971
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1291-1301Informations de copyright
© 2024 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.